塞来昔布对子宫内膜癌细胞增生和COX-2 mRNA表达的影响

 【目的 探讨塞来昔布对子宫内膜癌细胞HEC-1-B的作用及对COX-2 mRNA表达的影响。方法 采用细胞培养、MTT试验研究不同浓度的塞来昔布对人类子宫内膜癌细胞HEC-1-B生长的抑制作用，通过RT-PCR法检测塞来昔布作用后COX-2 mRNA表达的变化。结果 塞来昔布能够有效地抑制HEC-1-B细胞的生长，并呈一定的剂量和时间依赖关系，同时能够抑制其COX-2 mRNA表达，20 μmol／L和50 μmol／L塞来昔布对COX-2 mRNA表达的抑制率分别为25.92 ％和50.81％。结论 塞来昔布可能是通过降低COX-2 mRNA的表达而抑制子宫内膜癌细胞的生长。     

SU11274抑制人子宫内膜癌细胞增殖的分子机制

目的:探索HGF/c-met传导通路抑制剂SU11274抑制子宫内膜癌细胞增殖的分子机制。方法:使用不同浓度SU11274（0.5 μmol/L、1.0 μmol/L、1.5 μmol/L）作用ishikawa 和HEC-1B 两种细胞株1小时后，加入40 ng/ml的HGF，继续培养48小时，然后使用RT-PCR检测c-met、Survivin、XIAP水平以及Western blot检测细胞中Survivin、XIAP蛋白表达水平。结果:ishikawa细胞c-met低表达，而HEC-1B细胞c-met明显高表达，HEC-1B细胞中c-met mRNA表达量为ishikawa中的2.5倍。SU11274可以使HEC-1B、ishikawa细胞的Survivin、XIAP蛋白表达下调，呈现剂量依赖性，并且在HEC-1B细胞中，该下调作用明显强于ishikawa细胞（P<0.05）。结论:SU11274可以通过下调HGF/c-met传导通路中Survivin、XIAP的表达来抑制人子宫内膜癌细胞增殖。     

乳腺癌中COX-2表达及其抑制剂塞来昔布对乳腺癌细胞系增生和凋亡的影响

目的为进一步观察COX-2对乳腺癌的作用,我们检测了乳腺癌组织、乳腺癌细胞株MCF-7和B37中COX-2的表达,并观察选择性COX-2抑制剂塞来昔布对乳腺癌细胞株生长和凋亡的影响。方法应用免疫组织化学染色的方法检测132例乳腺癌组织标本中COX-2蛋白的表达;应用免疫细胞化学染色、原位杂交、逆转录多聚酶联反应（RT-PCR）的方法,分别检测COX-2蛋白和mRNA在乳腺癌细胞株MCF-7、B37中的表达;采用MTT法、AO/EB双荧光染色法和流式细胞术,研究塞来昔布对乳腺癌细胞增殖和凋亡的影响。结果52.3%(69/132)的乳腺癌组织标本表达COX-2蛋白;在乳腺癌细胞株MCF-7和B37中均有COX-2的表达,25μmol/L塞来昔布作用72h后,COX-2表达明显减少;25、50、100μmol/L的塞来昔布与MCF-7细胞作用72h,生长抑制率分别为36.3%、57.7%、74.5%。100μmol/L塞来昔布作用72h后,MCF-7细胞凋亡率为38.5％。结论乳腺癌组织和乳腺癌细胞株MCF-7、B37中存在COX-2的表达;塞来昔布可抑制乳腺癌细胞增殖,并促进细胞凋亡,塞来昔布可能作为新的药物治疗乳腺癌。     

SU11274对人子宫内膜癌细胞抑制作用的研究

目的:研究SU11274对子宫内膜癌细胞增殖及凋亡的影响。方法:使用不同浓度SU11274（0.5 μmol/L、1.0 μmol/L、1.5 μmol/L、2.0 μmol/L）作用Ishikawa 和HEC-1B 两种细胞株1小时后，加入40 ng/ml的HGF，继续培养12、24、48小时，随后使用MTT法检测SU11274对子宫内膜癌细胞增殖的影响，并使用Annexin V-FITC法检测SU11274对细胞凋亡的影响。结果:SU11274均能抑制两种细胞的增殖，呈浓度依赖性，对HEC-1B细胞的增殖抑制作用明显高于Ishikawa细胞，差异具有统计学意义（P＜0.05）。SU11274可以使HEC-1B细胞株早期及中晚期凋亡细胞的百分比均增加，且具有剂量依赖效应关系，并不会增加Ishikawa细胞株的凋亡率（P＞0.05）。结论:SU11274是一种十分高效的抑制子宫内膜癌细胞生长的生物活性物质，主要通过诱导细胞的早期及中晚期凋亡来发挥抗肿瘤作用。并且对ER(-)的HEC-1B细胞株具有特异性的抑制作用。     

丁酸钠对子宫内膜癌细胞增殖及NDRG1蛋白表达的影响

目的 探讨组蛋白去乙酰化酶抑制剂丁酸钠（NaB）对子宫内膜癌细胞株HEC-2B增殖及N-myc下游调节基因1（NDRG1）蛋白表达的影响。方法 采用MTT比色法检测不同浓度的NaB处理HEC-2B细胞48、72h后细胞的生长情况; 荧光倒置显微镜下观察NaB处理48h后细胞的形态改变;Western blotting法检测NaB处理48h后细胞中NDRG1蛋白的表达情况。结果 NaB能够抑制HEC-2B细胞的增殖,并呈浓度和时间依赖性（P＜0.05）。不同浓度NaB作用48h后,荧光倒置显微镜下 HEC-2B细胞出现细胞凋亡的特征性改变。随着NaB浓度的增加,HEC-2B细胞中NDRG1蛋白的表达水平逐渐下调。结论 NaB能够抑制子宫内膜癌HEC-2B细胞的增殖,可能与下调NDRG1蛋白的表达有关。     

The Inhibition Effect of Triptolide on Human Endometrial Carcinoma Cell Line HEC-1B: a in vitro and in vivo Studies

Background: To investigate the inhibitory effect and the underlying mechanism of triptolide on culturedhuman endometrial carcinoma HEC-1B cells and corresponding xenograft. Materials and Methods: For in vitrostudies, the inhibition effect of proliferation on HEC-1B cell by triptolide was determined by MTT assay; cellcycle and apoptosis of the triptolide-treated and untreated cells were detected by flow cytometry. For in vivostudies, a xenograft tumor model of human endometrial carcinoma was established using HEC-1B cells, thenthe tumor-bearing mice were treated with high, medium, and low-dose (8 μg, 4 μg and 2 μg/day) triptolide orcisplatin at 40 μg/day or normal saline as control. The mice were treated for 10-15 days, during which body weightof the mice and volume of the xenograft were weighted. Then expression of Bcl-2 and vascular endothelial growthfactor (VEGF) was analyzed by SABC immunohistochemistry. Results: Cell growth was significantly inhibitedby triptolide as observed by an inverted phase contrast microscope; the results of MTT assay indicated thattriptolide inhibits HEC-1B cell proliferation in a dose and time-dependent manner; flow cytometry showed thatlow concentration (5 ng/ml) of triptolide induces cell cycle arrest of HEC-1B cells mainly at S phase, while higherconcentration (40 or 80 ng/ml) induced cell cycle arrest of HEC-1B cells mainly at G2/M phase, and apoptosisof the cells was also induced. High-dose triptolide showed a similar tumor-inhibitory effect as cisplatin (-50%);high-dose triptolide significantly inhibited Bcl-2 and VEGF expression in the xenograft model compared tonormal saline control (P<0.05). Conclusions: triptolide inhibits HEC-1B cell growth both in vitro and in mousexenograft model. Cell cycle of the tumor cells was arrested at S and G2/M phase, and the mechanism may involveinduction of tumor cell apoptosis and inhibition of tumor angiogenesis.     

miR-195-5p靶向FGF2 抑制子宫内膜癌HEC-1B细胞恶性生物学行为

目的：探讨miR-195-5p 通过靶向FGF2 抑制子宫内膜癌HEC-1B细胞增殖、凋亡、侵袭和迁移的分子机制。方法：HEC-1B细胞培养与转染完成后分为4 组：HEC-1B组、miR-195-5p mimic组、pLV-FGF2 组和miR-195-5p+FGF2 组。qRT-PCR检测细胞miR-195-5p 和FGF2 mRNA水平,荧光素酶实验验证miR-195-5p 与FGF2 的靶向关系,Western blotting 检测FGF2 表达水平,CCK-8 法检测HEC-1B细胞增殖水平,流式细胞术检测HEC-1B细胞凋亡率,Transwell 实验检测HEC-1B细胞侵袭能力,划痕实验检测HEC-1B细胞迁移能力。结果：与HEC-1B组相比,miR-195-5p mimic 组miR-195-5p 表达升高、FGF2 mRNA水平下降(均P< 0.01);miR-195-5p 可直接靶向FGF2。与HEC-1B组相比,miR-195-5p mimic 组FGF2 的蛋白表达水平下降,pLV- FGF2 组FGF2 的蛋白水平明显上升,且miR-195-5p+FGF2 组FGF2 的蛋白表达水平低于pLV- FGF2 组(均P< 0.01)。miR-195-5p mimic 组细胞增殖水平低于HEC-1B组,pLV-FGF2 组细胞增殖水平高于HEC-1B组(均P< 0.01)。与HEC-1B组相比,miR-195-5p mimic 组细胞凋亡率增加,pLV- FGF2 组细胞凋亡率降低,且miR-195-5p+ FGF2 组细胞凋亡率高于pLV- FGF2 组(均P< 0.01)。与HEC-1B组相比,miR-195-5p mimic 组每个视野下的侵袭细胞数和划痕愈合率下降,pLV- FGF2 组每个视野下的侵袭细胞数和划痕愈合率上升,且miR-195-5p+FGF2 组每个视野下的侵袭细胞数和划痕愈合率低于pLV- FGF2 组(均P<0.01)。结论: miR-195-5p 通过靶向FGF2 抑制子宫内膜癌HEC-1B细胞的增殖、侵袭和迁移并促进细胞凋亡,其作为子宫内膜癌的治疗靶点。     

脂质体转染survivin反义寡核苷酸对K562细胞增殖及凋亡的作用

目的:观察脂质体转染survivin反义寡核苷酸(ASODN)对白血病细胞K562的增殖及凋亡的影响。方法:人工合成survivin硫代ASODN,通过脂质体转染K562细胞,倒置显微镜下观察细胞形态学变化;用MTT法观察转染前后对细胞增生的影响;用细胞凋亡检测法(POD)观察细胞凋亡;RT-PCR检测survivin mRNA的表达。结果:(1)survivin ASODN抑制K562细胞增殖呈时间和剂量依赖性;(2)survivin ASODN可诱导K562细胞的凋亡,凋亡指数呈浓度依赖性;(3)survivinASODN处理组K562细胞survivin mRNA的表达水平显著下降。结论:脂质体转染survivin ASODN能够明显抑制K562细胞增殖,且能诱导细胞凋亡。survivin可能成为肿瘤基因治疗的一个新靶点。     

YM155对肝癌HepG2细胞增殖和凋亡的影响

目的:探讨YM155对肝癌HepG2细胞增殖和凋亡的影响及可能的机制。方法:采用CCK-8法检测细胞生长抑制率；应用流式细胞仪检测细胞凋亡率的变化；Western blot法检测细胞中蛋白表达的变化，实时定量RT-PCR检测survivin mRNA表达的变化。结果:YM155对人肝癌HepG2细胞的生长抑制作用呈现剂量和时间依赖性。流式细胞术结果显示，HepG2细胞凋亡率明显升高,呈现剂量依赖性。YM155可引起survivin mRNA及蛋白表达下降，而caspase-3、caspase-9和PARP蛋白表达上升。结论:YM155可以抑制人肝癌HepG2细胞的增殖并促进其凋亡，其机制可能是通过激活caspase凋亡途径来实现。     

环氧合酶-2抑制剂对人肝癌细胞株的体外研究

目的:观察环氧合酶-2(cyclooxygenase-2,COX-2)抑制剂Celecoxib对人肝癌细胞株增殖和凋亡的影响以及COX-2、Survivin和MDR1/P-gp表达水平的变化,探讨COX-2抑制剂治疗肝癌的作用机制。方法:MTT法检测细胞增殖状态;免疫组化法测定细胞中PCNA和COX-2表达;透射电镜及流式细胞仪观察Celecoxib诱导肝癌细胞凋亡的作用、对细胞周期的影响以及P-gp表达的变化;进一步用RT-PCR检测Survivin和COX-2mRNA在药物处理前后表达的变化。结果:人肝癌细胞系Hep-G2和BEL-7402中COX-2均有显著表达,Celecoxib呈时间和剂量依赖性抑制肝癌细胞增殖,促进其凋亡;细胞周期分布改变,G0/G1期细胞比例增加;肝癌细胞凋亡过程中,COX-2和Survivin基因的表达显著下调,P-gp表达减弱。结论:COX-2抑制剂Celecoxib可能通过下调COX-2、Survivin和P-gp表达,改变细胞周期分布,抑制细胞增殖、诱导细胞凋亡而发挥抗肿瘤作用。     

抑制survivin基因对人卵巢癌SKOV3细胞顺铂药物敏感性的影响(英文)

目的:探讨应用RNA i技术下调survivin基因对人卵巢癌SKOV3细胞增殖、凋亡及顺铂敏感性的影响。方法:构建survivin基因shRNA真核表达载体,转染人卵巢癌SKOV3细胞。定量PCR和Western blotting观察SKOV3细胞survivin mRNA和蛋白表达的改变;噻唑蓝(MTT)检测细胞增殖活性和药物敏感性;流式细胞仪检测细胞凋亡。结果:SKOV3-siRNA组细胞survivin mRNA及蛋白表达下降,同时细胞增殖能力明显降低,细胞凋亡率显著增加(P<0.05)。SKOV3-siRNA组细胞对顺铂的化学敏感性升高,顺铂的IC50值降低(P<0.05)。结论:下调survivin基因表达能够抑制卵巢癌SKOV3细胞增殖能力,诱导细胞凋亡,增强细胞顺铂药物敏感性。因此,survivin基因可能成为抗肿瘤治疗的潜在靶点。     

AP-4基因表达下调抑制子宫内膜癌细胞侵袭和迁移能力

目的:观察靶向抑制激活增强子结合蛋白-4(AP-4)基因的表达对子宫内膜癌细胞侵袭和迁移能力的影响。方法:用荧光定量PCR(qRT-PCR)检测人子宫内膜癌细胞株HEC-1A、RL-952、HEC-1B、ishikawa中AP-4基因的表达水平。采用脂质体介导的细胞转染法将AP-4 siRNA转染至HEC-1A细胞,同时设置转染对照。转染48 h后,采用qRT-PCR和蛋白印迹法(Western blot)检测转染后各组HEC-1A细胞中AP-4的表达水平,通过细胞划痕实验观察转染后各组细胞迁移情况,采用Transwell实验检测转染后各组细胞侵袭能力。采用Western blot检测转染后各组细胞中上皮细胞标志分子E-钙粘蛋白(E-cadherin)和间充细胞标志分子N-钙粘素(N-cadherin)、波形蛋白(Vimentin)表达水平。结果:AP-1基因在四株子宫内膜癌细胞中均有表达,在HEC-1A细胞中相对表达水平最高(P<0.05),用于后续转染实验。qRT-PCR和Western blot结果均显示转染AP-4 siRNA能够成功抑制HEC-1A细胞中AP-1 mRNA和蛋白的表达(P<0.05)。Transwell实验显示转染AP-4 siRNA后HEC-1A细胞侵袭能力明显受到抑制(P<0.05)。划痕实验显示转染AP-4 siRNA后HEC-1A细胞迁移能力明显受到抑制(P<0.05)。Western blot结果显示转染AP-4 siRNA后HEC-1A细胞中N-cadherin和Vimentin蛋白水平降低,E-cadherin蛋白水平升高,抑制了上皮间质转化(EMT)过程(P<0.05)。结论:AP-4基因表达下调能够有效抑制子宫内膜癌细胞的侵袭和迁移能力,该过程可能与逆转细胞EMT过程有关。     

Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone

The expression of growth hormone-releasing hormone (GHRH) and its receptors has been demonstrated in peripheral tissues as well as CNS. Recently, the functional splice variant SV1 of GHRH receptor was identified in various human cancers and cancer cell lines. Although antineoplastic activity of GHRH antagonists has been clearly demonstrated, the mechanism of action is incompletely understood. The objective of this study was the investigation of direct anti-proliferative effect of GHRH antagonist MZ-5-156 on HEC-1A human endometrial cancer cell line and the elucidation of underlying mechanisms. RT-PCR revealed the expression of mRNA for GHRH and SV1 of GHRH receptor in HEC-1A cells. MZ-5-156, at concentrations between 10(-7) and 10(-5) M, had a dose-dependent antiproliferative effect on HEC-1A cells, as determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, (MTS) assay. Hoechst 33342 staining and flow cytometric analysis indicated that MZ-5-156, at 10(-6) M, induced apoptosis in HEC-1A cells after 48 h of treatment. Western blot analysis of apoptosis-related proteins demonstrated that treatment with MZ-5-156 (10(-6) M) for 48 h significantly increased the protein levels of Fas, phospho-p53 (Ser46), p53AIP1 (p53-regulated Apoptosis-Inducing Protein 1), and caspase-8, -9, and -3, and decreased the protein level of Bcl-2. These results demonstrate that MZ-5-156 can directly inhibit the proliferation of human endometrial cancer cells, which express mRNA for GHRH and SV1 of GHRH receptor, presumably through the induction of p53-dependent apoptosis coupled with the up-regulation of Fas, phospho-p53 (Ser46), p53AIP1, and caspase-8, -9, and -3, and the down-regulation of Bcl-2.     

Effects of RNA interference targeting four different genes on the growth and proliferation of nasopharyngeal carcinoma CNE-2Z cells

To explore the effects of RNA interference targeting four different genes (VEGF, C-myc, Survivin, hTERT) on the growth and proliferation of nasopharyngeal carcinoma (NPC) CNE-2Z cells. Fluorescein-labeled short-hairpin (sh)RNA plasmids together and separately targeting VEGF, C-myc, Survivin and hTERT were built and respectively called plasmid-shVEGF-shC-myc-shSurvivin-shhTERT, plasmid-shVEGF, plasmid-shC-myc, plasmid-shSurvivin, plasmid-shhTERT. These plasmids were respectively transfected into human NPC CNE-2Z cells and xenograft tumors in nude mice. The expression of plasmids in NPC CNE-2Z cells and xenograft tumors was observed. Cell proliferation was detected with MTT assay. The mRNA and protein expression were determined by real-time PCR and western blot, respectively. The effects of plasmids on the biological behavior of CNE-2Z cells were observed with transwell invision chamber models. Apoptosis was determined with flow cytometer. The inhibitory effect of plasmids on xenograft tumors was observed in nude mice. The plasmid containing four different shRNAs could significantly inhibit CNE-2Z cell proliferation and decrease invasion ability in vitro compared with plasmids with each single shRNA (P<0.05). The plasmid containing four different shRNAs could simultaneously downregulate VEGF, C-myc, surviving, hTERT mRNA and protein expression in the CNE-2Z cells. The multiple gene shRNA could more significantly induce cell apoptosis than each single shRNA, respectively (P<0.05). The combinative silencing of these four genes had a better inhibitory effect on xenograft tumors than the silencing of each single shRNA (P<0.05). RNA interference targeting multiple genes can effectively inhibit NPC proliferation and induce apoptosis, which provides an experiment basis for NPC gene therapy.     

Celecoxib联合羟基喜树碱对缺氧诱导的人肝癌细胞增殖与凋亡的影响

目的:探讨选择性环氧合酶-2(COX-2)抑制剂Celecoxib联合羟基喜树碱对缺氧诱导的人肝癌细胞株SMMC-7721细胞增殖和凋亡的影响。方法:应用三气培养箱在缺氧环境下培养人肝癌细胞株SMMC-7721细胞。预实验筛选Celecoxib、羟基喜树碱最小有效终浓度,设24、48、72小时为干预时间并筛选最佳作用时间。分别以Celecoxib及羟基喜树碱单独实验筛选的最小有效浓度为联合组浓度;以Celecoxib单独实验筛选最佳作用时间为实验时间。倒置显微镜观察细胞形态学变化;应用四氮唑盐比色法(MTT法)监测细胞增殖活力;Annexin V/PI双染色法检测细胞凋亡;免疫细胞化学法（SP法）检测凋亡蛋白Bax、Bcl-2、COX-2的表达。结果:不同浓度Celecoxib及不同时间对SMMC-7721细胞表现出的生长抑制作用呈剂量依赖性及时间依赖性。Celecoxib（30 mg/L)单用在作用72 h时即可抑制SMMC-7721细胞的增殖。选72 h为作用时间,不同浓度羟基喜树碱对SMMC-7721细胞表现出的生长抑制作用呈剂量依赖性,浓度为0.625 μmol/L羟基喜树碱即可抑制SMMC-7721细胞的增殖。选用羟基喜树碱(0.625 μmol/L)与Celecoxib（30 mg/L)联合作用72 h时,联合抑制作用结果呈现协同作用(Q>1.15)。流式细胞仪检测分析,两种药物均可有效诱导 SMMC-7721细胞的凋亡,并且在上述浓度联合作用时具有协同效应。免疫细胞化学结果显示,Celecoxib（30 mg/L)组和联合用药组细胞质内棕黄色颗粒较对照组染色浅,表明Bcl-2和COX-2蛋白表达有所下降,而Bax蛋白表达在Celecoxib（30 mg/L)和联合用药组中黄色颗粒的阳性细胞较对照组增多,表明Bax蛋白表达有所上调;并且此变化与Celecoxib（30 mg/L)组比较联合用药组有协同作用(P<0.05)。结论:缺氧状态下Celecoxib与羟基喜树碱对SMMC-7721细胞株均有抑制增殖与促进凋亡作用,并且两者联合作用有协同作用;Celecoxib的作用机制除了抑制COX-2外,还可能与下调Bcl-2、上调Bax的表达有关。     

塞来昔布对NB4细胞增殖、凋亡及VEGF表达的影响

目的 探讨塞来昔布对急性早幼粒细胞白血病细胞的抑制作用及可能机制.方法 不同浓度塞来昔布处理急性早幼粒细胞白血病细胞株NB4,MTT法检测塞来昔布作用后细胞的增殖情况.采用流式细胞术测定NB4细胞周期分布及凋亡;Western blot检测细胞凋亡相关蛋白Bcl-2表达以及RTPCR检测塞来昔布作用对VEGF、HIF-1α在mRNA水平的表达.结果 MTT显示塞来昔布对NB4细胞生长有明显抑制作用.20～80 μmol/L塞来昔布作用24 h,NB4细胞G0/G1期比例明显升高,而S期细胞比例下降(P＜0.05);塞来昔布处理组细胞凋亡率明显高于对照组,Western blot显示Bcl-2蛋白表达下调(P＜0.05);RT-PCR显示塞来昔布可抑制VEGF及HIF 1α的mRNA表达.结论 塞来昔布在体外可抑制急性早幼粒细胞白血病细胞增殖并诱导凋亡.     

小干扰RNA阻断周期蛋白依赖激酶4对子宫内膜癌细胞生物学行为的影响

背景与目的：细胞周期蛋白依赖激酶4(cyclin-dependent kinase 4,CDK4)是调控细胞周期进程的重要激酶之一,有实验报道其在子宫内膜癌中呈高表达,但是其在子宫内膜癌细胞中的生物学功能及其可能机制还不十分明确。本研究旨在通过小干扰RNA(small interfering RNA,siRNA)沉默CDK4表达,并检测其对人子宫内膜癌HEC-1B细胞生物学行为的影响及其可能机制。方法：将化学合成的CDK4-siRNA转染至HEC-1B细胞;实时荧光定量PCR法检测转染前后细胞中CDK4的mRNA表达量变化;Western blot检测转染前后细胞CDK4、视母细胞瘤基因(retinoblastoma gene,Rb)及其下游p-Rb的蛋白表达量的变化;分别采用CCK-8法、流式细胞仪、Transwell肿瘤细胞侵袭实验检测细胞增殖、周期、凋亡以及侵袭能力的变化。结果：转染后HEC-1B细胞中CDK4 mRNA及蛋白表达均明显下降(P<0.01);抑制CDK4表达后,抑制HEC-1B细胞的增殖及侵袭,转染si-CDK4组细胞发生侵袭数为(117±21)个,而转染si-control组及未处理组分别为(269±39)个和(262±35)个,差异具有统计学意义(P<0.01);细胞转染后早期凋亡率为(21.7±3.5)%,较未处理组［(12.4±2.1)%］和si-control组［(11.8±1.9)%］明显增加(P<0.01);细胞周期分布发生变化,G₁期比例增加(P<0.01),S期细胞比例降低(P<0.01);进一步的Western blot结果显示,抑制CDK4表达后,细胞内p-Rb表达下降,但是总Rb表达无明显变化。结论：针对CDK4基因的特异性小RNA干扰片段能够下调CDK4基因在子宫内膜癌细胞中的表达,抑制肿瘤生物学进程。     

抑制Survivin基因对人卵巢癌SKOV3细胞增殖和凋亡的影响

目的:探讨应用RNAi技术沉默Survivin基因对人卵巢癌SKOV3细胞的影响。方法:构建Survivin基因shRNA真核表达载体,转染人卵巢癌SKOV3细胞。RT-PCR及Western blot检测Survivin基因的表达,MTT实验、流式细胞仪检测细胞增殖、凋亡的变化。结果:siRNA实验组细胞Survivin蛋白及mRNA表达水平明显下降,细胞增殖能力显著降低,细胞凋亡率显著升高。结论:应用RNAi技术沉默Survivin基因可以降低卵巢癌SKOV3细胞Survivin基因的表达,进而抑制肿瘤细胞的生长、增殖并诱导细胞凋亡。因此,Survivin基因可能成为抗肿瘤治疗的潜在靶点。     

Transforming growth factor gene expression in human endometrial adenocarcinoma cells: regulation by progestins.

In an attempt to understand the antiproliferative effects of progestins in endometrial cancer, we have examined the effects of the potent progestin, medroxyprogesterone acetate (MPA), on the cell proliferation and the expression of transforming growth factor (TGF) alpha and beta genes in human endometrial adenocarcinoma cell lines. The two cell lines used were Ishikawa, var 1, and HEC-50. In addition, the effects of exogenous TGF-alpha and anti-epidermal growth factor (EGF) receptor monoclonal antibody on cell proliferation were determined. Incubation of both cell lines with MPA resulted in a time- and dose-dependent inhibition of cell proliferation. Half-maximal growth inhibition was observed at 0.6 nM. In Ishikawa cells, the relative abundance of TGF-alpha was significantly reduced by MPA. A significant decrease in TGF-alpha mRNA was apparent 6 h after exposure to MPA and a further decrease was seen 12-24 h after addition of the progestin. The concentration of TGF-alpha immunoreactivity in conditioned medium of MPA-treated cells was also significantly reduced compared to control cultures. MPA had no effect on TGF-alpha expression by HEC-50 cells. EGF mRNA was not detected by Northern blot analysis in either cell type. MPA had no significant effect on EGF receptor mRNA abundance but resulted in a small increase in EGF receptor number in Ishikawa cells. Anti-EGF receptor monoclonal antibody (0.6-6 nM) inhibited Ishikawa cell growth but had no effect on HEC-50 cell proliferation. Exogenous TGF-alpha stimulated proliferation of both cell lines, but Ishikawa cells were significantly more sensitive to exogenous TGF-alpha than HEC-50 cells. Furthermore, TGF-alpha could reverse the growth inhibitory effects of MPA on Ishikawa cells. A decrease in TGF-beta mRNA abundance was also observed in MPA-treated Ishikawa and HEC-50 cells. This effect was of small magnitude, variable, and only observed after prolonged exposure to MPA. These observations are consistent with the hypothesis that the antiproliferative effects of progestins on Ishikawa cells are mediated by decreased expression and autocrine action of TGF-alpha. Since similar growth inhibition is also seen in the HEC-50 cells in which progestins have no effect on TGF-alpha expression, additional mechanisms are likely to be involved in the antiproliferative effects of progestins in human endometrial cancer.